GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.

The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).

Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.

The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.

MOMA-313 is under development for the treatment of solid tumors including metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer. It acts by targeting DNA polymerase theta.

CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Relapsed Multiple Myeloma.